Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01242267 · ClinicalTrials.gov registry record · Phase 1
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
A Phase 1 study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01242267 is a Phase 1 study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 29 participants.
The verdict
NCT01242267, a Phase 1 study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The primary objective of this study is to: • Determine the maximum tolerated dose of thalidomide used in conjunction with dose-intense melphalan, bortezomib and autologous (syngeneic) HSC support in the salvage therapy of patients who failed a prior treatment with dose-intense melphalan The secondary objectives of this study are to: * Determine the toxicities resulting from administration of combinations of thalidomide, bortezomib and melphalan * Determine the complete response (CR) and very good partial response (VgPR) rate in patients undergoing ASCT using thalidomide, bortezomib and melphalan * Evaluate the treatment-free interval after treatment with the combination of thalidomide, bortezomib and melphalan
Interventions
- DRUG Thalidomide+Melphalan +Bortezomib+stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-05-11 |
| Est. Completion | 2016-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01242267
The ClinicalTrials.gov registry entry for NCT01242267 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide+Melphalan +Bortezomib+stem cell transplant is the first listed.
NCT01242267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01242267 about?
NCT01242267 is a clinical study titled "Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT". The primary objective of this study is to: • Determine the maximum tolerated dose of thalidomide used in conjunction with dose-intense melphalan, bortezomib and autologous (syngeneic) HSC support in the salvage therapy of patients who failed a prior treatment with dose-intense melphalan The second...
What is the current status of trial NCT01242267?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2010-05-11. Estimated completion is 2016-01-20.
What interventions are being tested in trial NCT01242267?
The interventions under investigation include: Thalidomide+Melphalan +Bortezomib+stem cell transplant (DRUG).
Who is sponsoring clinical trial NCT01242267?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.